|
Steatohepatitis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We used real-time polymerase chain reaction (PCR) analysis to analyze the hepatic expression of PNPLA3 and lipid metabolism-related genes in 55 morbidly obese subjects with normal liver histology (NL, n = 18), simple steatosis (SS, n = 20), and non-alcoholic steatohepatitis (NASH, n = 17).
|
27128907 |
2016 |
|
Steatohepatitis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Steatotic HCC did not differ from HCC without significant steatosis in immunohistochemical expression of FABP1 and SHH and PNPLA3 gene polymorphism.
|
27380543 |
2016 |
|
Steatohepatitis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The up-regulation of expression of hepatic genes related to liver steatosis (CPT1A, FASN, LEPR, RXRA, IGFBP1, PPARGC1A and SLC2A4) was detected in our rhesus model, as was the down-regulation of such genes (CYP7A1, HMGCR, GCK and PNPLA3) and the up-regulation of expression of hepatic genes related to liver cancer (E2F1, OPCML, FZD7, IGFBP1 and LEF1).
|
26442469 |
2015 |
|
Steatohepatitis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
PNPLA3 expression in Hispanics could be decisive in NAFLD pathogenesis, it's highly prevalent and it's a key to condition and determine the spectrum associated, SS, NASH and fibrosis.
|
29055919 |
2018 |
|
Steatohepatitis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Reducing pnpla3 expression prevented hepatic steatosis, which could be attributed to decreased fatty acid esterification measured by the incorporation of [U-(13) C]-palmitate into hepatic triglyceride.
|
23175050 |
2013 |
|
Steatohepatitis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Our results provide evidence that PNPLA3 expression is an early signal/signature of carbohydrate-induced lipogenesis, but its expression is not associated with steatosis per se.
|
25060692 |
2014 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
PNPLA3 may be an important key to understand the mechanisms discriminating fatty liver with and without metabolic consequences.
|
19651814 |
2009 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recent studies have implicated PNPLA3 in the pathogenesis of hepatic steatosis.
|
20480550 |
2010 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
The PNPLA3 p.148 I/M or M/M variants and CD4(+) cell count were the only independent predictors of severe steatosis in patients with HCV non-3 genotypes.
|
26806136 |
2016 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
PNPLA3 carriers showed higher steatosis, portal inflammation and HpSC niche activation compared to wild-type patients.
|
29150621 |
2017 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Although African Americans are less susceptible to fatty liver than European Americans, PNPLA3 appears to be a risk locus for hepatic steatosis in diabetic African Americans.
|
21665509 |
2011 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
IL28B and PNPLA3 are associated with hepatic steatosis prevalence and severity in Caucasians with G1 HCV, suggesting differing potential genetic risk pathways to steatosis.
|
22543885 |
2012 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overall, one-third of HIV/HCV-coinfected patients are affected by HS with PI-based ART and PNPLA3 impacting on HS prevalence.
|
31067123 |
2019 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Steatohepatitis was associated with all-cause mortality [Hazard ratio (HR) 3.1, 95%CI: 1.3-7.3, P = 0.006] and HCC (HR 2.8, 95%CI: 0.9-9.2, P = 0.078), but no significant association was observed for PNPLA3.
|
25284145 |
2015 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Multivariate logistic regression identified PNPLA3 G allele (OR: 2.469, CI 95%: 1.203-5.068; p=0.014) and pediatric age (OR: 4.348; 1.577-11.905; p=0.004) as independent variables associated with moderate/severe steatosis.
|
25678388 |
2015 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Conclusion: Taken together, these findings are consistent with a model in which PNPLA3(148M) promotes steatosis by CGI-58-dependent inhibition of ATGL on LDs.
|
30802989 |
2019 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Based on a large monocentric cohort of Caucasian heavy drinkers we could recently provide evidence that PNPLA3 GG primarily correlated with signs of liver damage (steatohepatitis, ballooning) but less with steatosis.
|
30362098 |
2019 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Taken together, our results show that the steatosis associated with PNPLA3(148M) is caused by accumulation of PNPLA3 on LDs.
|
31019090 |
2019 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
ASO-mediated silencing of Pnpla3 reduced liver steatosis (p = 0.038) in homozygous Pnpla3 148M/M knock-in mutant mice but not in wild-type littermates fed a steatogenic high-sucrose diet.
|
30772256 |
2019 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Translation of candidates from these studies into ALD has established a role for variants in genes including PNPLA3 and potentially TM6SF2 across the disease spectrum from steatosis, through cirrhosis to hepatocellular carcinoma.
|
26676812 |
2015 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
PNPLA3 was associated with a portal pattern of steatosis, inflammation and fibrosis.
|
30444569 |
2019 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In fact, the probability of more severe steatosis was higher (37%, 95% CI 26-48%) for the PNPLA3 M/M versus I/M genotype and lower (-12%, 95% CI -21% to -3%) for the I/I versus I/M genotype (Somers' D for repeated measures).
|
24074360 |
2013 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recent advances include the identification of PNPLA3 as a modifier of disease outcome across the full spectrum of NAFLD from steatosis to advanced fibrosis and hepatocellular carcinoma; and the discovery of TM6SF2 as a potential "master regulator" of metabolic syndrome outcome, determining not only risk of advanced liver disease, but also cardiovascular disease outcomes.
|
26378644 |
2015 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Steatosis in PNPLA3-associated NAFLD is not accompanied by features of metabolic syndrome.
|
24731669 |
2014 |
|
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We assessed the familial correlation of PRO-C3 concentration, the shared gene effects between PRO-C3 concentration and liver steatosis and fibrosis, and the association between PRO-C3 concentration and genetic variants in the patatin-like phospholipase domain-containing 3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2), membrane-bound O-acyltransferase domain-containing (MBOAT), and glucokinase regulator (CGKR) genes.
|
30859582 |
2019 |